Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 12-Month High at $8.00

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s share price hit a new 52-week high on Friday . The stock traded as high as $8.00 and last traded at $7.88, with a volume of 341944 shares changing hands. The stock had previously closed at $7.77.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Truist Financial reiterated a “buy” rating and set a $9.00 price target (up previously from $7.00) on shares of Amneal Pharmaceuticals in a research report on Monday, May 6th. The Goldman Sachs Group increased their price objective on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the company a “buy” rating in a report on Monday, May 6th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $8.25.

Amneal Pharmaceuticals Price Performance

The firm has a market capitalization of $2.48 billion, a P/E ratio of -13.88 and a beta of 1.23. The business’s fifty day moving average is $6.95 and its 200 day moving average is $6.27. The company has a current ratio of 1.65, a quick ratio of 0.97 and a debt-to-equity ratio of 121.31.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently modified their holdings of AMRX. ProShare Advisors LLC boosted its stake in shares of Amneal Pharmaceuticals by 8.6% during the 1st quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock valued at $133,000 after buying an additional 1,726 shares during the period. SG Americas Securities LLC raised its stake in shares of Amneal Pharmaceuticals by 18.8% in the 1st quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock valued at $122,000 after acquiring an additional 3,177 shares in the last quarter. Rothschild Investment LLC bought a new stake in Amneal Pharmaceuticals during the second quarter worth approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Amneal Pharmaceuticals by 13.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after buying an additional 4,115 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Amneal Pharmaceuticals by 6.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 81,264 shares of the company’s stock worth $493,000 after buying an additional 5,146 shares during the period. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.